Dr. Kropf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
125 Queens Rd
Ste 600
Charlotte, NC 28204Phone+1 980-302-6600Fax+1 980-302-6605
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2006 - 2009- UPMC Medical EducationResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003
Certifications & Licensure
NC State Medical License 2021 - 2025
PA State Medical License 2003 - 2021- American Board of Internal Medicine Hematology
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS Start of enrollment: 2013 Apr 01
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
- Join now to see all
Publications & Presentations
PubMed
- 28 citationsChimeric Antigen Receptor T-Cell TherapyNdiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick A. Brown
Journal of the National Comprehensive Cancer Network. 2018-09-01 - 783 citationsFunctional genomic landscape of acute myeloid leukaemiaJeffrey W. Tyner, Cristina E. Tognon, Daniel Bottomly, Beth Wilmot, Stephen E. Kurtz
Nature. 2018-10-17 - 280 citationsAcute myeloid leukemia, version 3.2019Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01
Journal Articles
- Functional Genomic Landscape of Acute Myeloid LeukaemiaMarc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
Lectures
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patie...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
